Skip to Content

  • Search

View Additional Section Content

A phase III, multicenter, randomized, double-blind, placebo-controlled safety study of xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite treatment with H1 antihistamines, H2 blockers, and/or leukotriene receptor antagonists

Principal Investigator(s)
Robert Anolik, M.D.

Clinical Trial Categories

  • Allergy
Research Center of Allergy and Asthma Specialists at 877-877-8839

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details